Uterine leiomyoma cytogenetically exhibits at least six chromosomally abnormal subgroups. The largest subgroup is characterized by deletions of the long arm of chromosome 7. Few molecular and fluorescence in situ hybridization data are available that have aimed at a better definition of the lesion.
Molecular and cytogenetic analysis of chromosome 7 in uterine leiomyomas
β Scribed by Dr. C. S. Ishwad; R. E. Ferrell; J. Davare; A. M. Meloni; A. A. Sandberg; U. Surti
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 393 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1045-2257
No coin nor oath required. For personal study only.
β¦ Synopsis
Uterine leiomyomas are benign tumors that arise clonally from smooth muscle cells of the myometrium. Cytogenetic studies of uterine leiomyomas have shown that about 40% have chromosome abnormalities and that deletion of 7q is a common finding. The observations suggest the possible location of a growth-suppressor gene within the 7q2 I -q22 region. Molecular genetic analysis of cytogenetically normal tumors has frequently shown somatic loss of specific tumor suppressor genes detected by loss of heterozygosity in the critical region. To test the hypothesis that chromosome region 7q2 I -q22 contains a growth-suppressor gene involved in the development of leiomyomas, we examined 92 leiomyomas for allelic loss of 7q markers spanning the cytogenetically defined critical region. Forty tumors with cytogenetically defined 79 deletion, 45 tumors without cytogenetically visible 7q deletion, and seven tumors with no cytogenetic information were examined for allelic l oss of loci D7S489, D7S440,075492, D7S5 18, D7S47 I, D7S466, and D7S530. Loss of heterozygosity for one or more of these loci was observed in 23 of 40 (57.5%) of the tumors with deletion of 7q and in 2 of 45 cases without a cytogenetically visible deletion. The tumors with cytogenetic deletion of 7q, but no loss of 7q2 I -q22 markers, were mosaics, with only a minority of cells containing the cytogenetic deletion. The critical region of loss is defined by the markers D7S518 and D7S471, each showing loss in approximately 50% of informative cases. These markers define a I0 cM region of 7q2 I -q22 that is consistent with the cytogenetically defined smallest region of overlap and exclude l oss of the MET oncogene locus and WNTI, the murine mammary tumor-virus integration site, from the critical region. Our results further define a region that is consistently lost in leiomyomas with cytogenetic deletion of chromosome arm 7q. This region may contain a tumor suppressor gene involved in the development of a subset of leiomyomas. Genes Chmmosorn Cancer 14.5145 (1995). 0 1395 Wiiey-Lia. inc.
π SIMILAR VOLUMES
## Abstract Leiomyomas are the most common gynecologic tumors in women, but very little is known about their molecular pathology. We used singleβstranded conformational polymorphism/heteroduplex analysis to analyze 42 unselected uterine leiomyomas for somatic mutations in all coding exons of the ge
Our cytogenetic findings in 175 uterine leiomyomas revealed 52 tumors with clonal chromosome abnormalities, eight of which did not belong to any well-delineated cytogenetic abnormal subgroup. However, an interstitial deletion of the long arm of chromosome 3 was found, as the sole chromosome abnormal
Uterine leiomyomas are the most prevalent tumor type in women of reproductive age and are the most common reason for hysterectomies. Although uterine leiomyomas are considered to be benign, they are a major public health concern for women. In contrast, leiomyosarcomas are rare but highly malignant u
Uterine leiomyoma is a benign smooth muscle tumor of the myometrium and is the most commonly encountered neoplasm in women of reproductive age. As for most benign tumors, the pathogenesis of leiomyoma remains obscure, especially at the molecular genetic level. The purpose of this study was to perfor
## Abstract Somatic interstitial deletions of chromosome segment 7q22βq31 in uterine leiomyomas are a frequent event, thought to be indicative of a tumor suppressor gene in the region. Previous LOH and CGH studies have refined this region to 7q22.3βq31, although the target gene has not been identif